Vaccine Research and Development Status
Status of global vaccine research and development (by vaccine type)
- Agency:
- nvi
- Licence:
- Creative Commons Attributions
- Category:
- ข้อมูลสาธารณะ
- Geographic coverage:
- ประเทศ
- Update frequency:
- เดือน
- Source portal:
- data_go_th
- Updated:
- 25/05/2026
English title machine-translated from the Thai original
States monthly, but the record has not been updated for 112 days (3 cycles)
The same record appears 1 more times on: gdcatalog — counted once here
What is in the file
First 10 of 62 rows · 11 columns
| Record_idtext | Vaccinetext | VaccineSubtext | VaccineCandidateNametext | VaccineStatustext | Highest Phasetext | Platformtext | Lead Developertext | Countrytext | Notetext | CreateDatetimestamp |
|---|---|---|---|---|---|---|---|---|---|---|
| ARV-DEN-001 | Dengue Vaccine | Tetravalent (DENV1-4) | Butantan-DV | Registered | Registered (Marketed) | Recombinant Live-attenuated Vaccine | Instituto Butantan | Brazil | Single-dose schedule; first single-dose dengue vaccine; ages | 2026-04-13T00:00:00 |
| ARV-DEN-002 | Dengue Vaccine | Tetravalent (DENV1-4) | Dengvaxia (CYD-TDV) | Registered | Registered (Marketed) | Recombinant Live-attenuated Vaccine | Sanofi Pasteur | France | 3-dose schedule (0, 6, 12 mo); YF17D backbone; restricted to | 2026-04-13T00:00:00 |
| ARV-DEN-003 | Dengue Vaccine | Tetravalent (DENV1-4) | QDENGA (TAK-003 / DENVax) | Registered | Registered (Marketed) | Recombinant Live-attenuated Vaccine | Takeda | Japan | 2-dose schedule (0, 3 mo); DENV-2 PDK-53 backbone (Inviragen | 2026-04-13T00:00:00 |
| ARV-DEN-004 | Dengue Vaccine | Tetravalent (DENV1-4) | DengiAll (Panacea Biotec) | Active/Ongoing | Clinical — Phase 3 | Recombinant Live-attenuated Vaccine | Panacea Biotec Limited; Indian Council of Medical Research | India | NIH TV003 backbone (licensed); single-dose; Phase 3 active i | 2026-04-13T00:00:00 |
| ARV-DEN-005 | Dengue Vaccine | Tetravalent (DENV1-4) | TDENV-LAV (WRAIR/GSK) | Completed | Clinical — Phase 2 | Live Attenuated Vaccine | Walter Reed Army Institute of Research; GlaxoSmithKline | USA / UK | Live attenuated; primate cell-derived; WRAIR/GSK collaborati | 2026-04-13T00:00:00 |
| ARV-DEN-006 | Dengue Vaccine | Tetravalent (DENV1-4) | NIH TV003/TV005 (rDENΔ30 / LATV) | Completed | Clinical — Phase 2 | Recombinant Live-attenuated Vaccine | National Institute of Allergy and Infectious Diseases (NIAID | USA | rDENΔ30 backbone (3' UTR deletion attenuation); developed by | 2026-04-13T00:00:00 |
| ARV-DEN-007 | Dengue Vaccine | Tetravalent (DENV1-4) | V181 (Merck/Butantan) | Completed | Clinical — Phase 2 | Recombinant Live-attenuated Vaccine | Merck | USA | Live attenuated; Merck/Butantan collaboration | 2026-04-13T00:00:00 |
| ARV-DEN-008 | Dengue Vaccine | Tetravalent (DENV1-4) | TDENV-PIV (WRAIR/GSK) | Completed | Clinical — Phase 1/2 | Purified Inactivated Vaccine | Walter Reed Army Institute of Research; GlaxoSmithKline | USA / UK | Purified inactivated; alum-adjuvanted; designed for prime-bo | 2026-04-13T00:00:00 |
First 10 of 62 rows · 11 columns
| Record_idtext | Vaccinetext | VaccineSubtext | VaccineCandidateNametext | VaccineStatustext | Highest Phasetext | Platformtext | Lead Developertext | Countrytext | Notetext | CreateDatetimestamp |
|---|---|---|---|---|---|---|---|---|---|---|
| ARV-DEN-001 | Dengue Vaccine | Tetravalent (DENV1-4) | Butantan-DV | Registered | Registered (Marketed) | Recombinant Live-attenuated Vaccine | Instituto Butantan | Brazil | Single-dose schedule; first single-dose dengue vaccine; ages | 2026-04-13T00:00:00 |
| ARV-DEN-002 | Dengue Vaccine | Tetravalent (DENV1-4) | Dengvaxia (CYD-TDV) | Registered | Registered (Marketed) | Recombinant Live-attenuated Vaccine | Sanofi Pasteur | France | 3-dose schedule (0, 6, 12 mo); YF17D backbone; restricted to | 2026-04-13T00:00:00 |
| ARV-DEN-003 | Dengue Vaccine | Tetravalent (DENV1-4) | QDENGA (TAK-003 / DENVax) | Registered | Registered (Marketed) | Recombinant Live-attenuated Vaccine | Takeda | Japan | 2-dose schedule (0, 3 mo); DENV-2 PDK-53 backbone (Inviragen | 2026-04-13T00:00:00 |
| ARV-DEN-004 | Dengue Vaccine | Tetravalent (DENV1-4) | DengiAll (Panacea Biotec) | Active/Ongoing | Clinical — Phase 3 | Recombinant Live-attenuated Vaccine | Panacea Biotec Limited; Indian Council of Medical Research | India | NIH TV003 backbone (licensed); single-dose; Phase 3 active i | 2026-04-13T00:00:00 |
| ARV-DEN-005 | Dengue Vaccine | Tetravalent (DENV1-4) | TDENV-LAV (WRAIR/GSK) | Completed | Clinical — Phase 2 | Live Attenuated Vaccine | Walter Reed Army Institute of Research; GlaxoSmithKline | USA / UK | Live attenuated; primate cell-derived; WRAIR/GSK collaborati | 2026-04-13T00:00:00 |
| ARV-DEN-006 | Dengue Vaccine | Tetravalent (DENV1-4) | NIH TV003/TV005 (rDEN?30 / LATV) | Completed | Clinical — Phase 2 | Recombinant Live-attenuated Vaccine | National Institute of Allergy and Infectious Diseases (NIAID | USA | rDEN?30 backbone (3' UTR deletion attenuation); developed by | 2026-04-13T00:00:00 |
| ARV-DEN-007 | Dengue Vaccine | Tetravalent (DENV1-4) | V181 (Merck/Butantan) | Completed | Clinical — Phase 2 | Recombinant Live-attenuated Vaccine | Merck | USA | Live attenuated; Merck/Butantan collaboration | 2026-04-13T00:00:00 |
| ARV-DEN-008 | Dengue Vaccine | Tetravalent (DENV1-4) | TDENV-PIV (WRAIR/GSK) | Completed | Clinical — Phase 1/2 | Purified Inactivated Vaccine | Walter Reed Army Institute of Research; GlaxoSmithKline | USA / UK | Purified inactivated; alum-adjuvanted; designed for prime-bo | 2026-04-13T00:00:00 |
Data files (4)
- XLSXสถานะการวิจัยและพัฒนาวัคซีน18 KB
สถานะการวิจัยและพัฒนาวัคซีนระดับโลก (แยกชนิดวัคซีน)
Download →A copy we hold, stored with its SHA-256 hash. The publisher's site remains the original.
- CSVสถานะการวิจัยและพัฒนาวัคซีน19 KB
สถานะการวิจัยและพัฒนาวัคซีนระดับโลก (แยกชนิดวัคซีน)
Download →A copy we hold, stored with its SHA-256 hash. The publisher's site remains the original.
- JSONสถานะการวิจัยและพัฒนาวัคซีน32 KB
สถานะการวิจัยและพัฒนาวัคซีนระดับโลก (แยกชนิดวัคซีน)
Download →A copy we hold, stored with its SHA-256 hash. The publisher's site remains the original.
- XLSXข้อมูลอธิบายสถานะการวิจัยและพัฒนาวัคซีน12 KB
ข้อมูลอธิบายสถานะการวิจัยและพัฒนาวัคซีนระดับโลก (แยกชนิดวัคซีน)
Download →A copy we hold, stored with its SHA-256 hash. The publisher's site remains the original.